edoc-vmtest

Trial design : how must we move ahead?

Seibold, J. R. and Tyndall, A. and Furst, D. E.. (2008) Trial design : how must we move ahead? Rheumatology, Vol. 47, Suppl. 5 , v57-58.

[img] PDF - Published Version
59Kb

Official URL: http://edoc.unibas.ch/dok/A6006335

Downloads: Statistics Overview

Abstract

Scleroderma is clinically heterogeneous and a variety of plausible mechanisms of disease have been hypothesized. Recent years have witnessed a significant improvement in overall survival although all of the gains in management have been therapies for specific organ involvement, e.g. renal crisis and pulmonary arterial hypertension. Future studies will rely on improved clinical science, which involves structured validation of proposed measures of outcome; development of a combined response index; and further refinement of specific subsets of disease expression. Immunoablation with stem cell reconstitution is an example of aggressive therapy chosen as appropriate for a particularly severe disease subset and in whom the pilot data are encouraging. Good science and clinical ethics force continued consideration of equipoise between risk and benefit.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Rheumatologie FPS (Tyndall)
UniBasel Contributors:De Vere-Tyndall, Alan
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Oxford University Press
ISSN:1462-0324
Note:Publication type according to Uni Basel Research Database: Journal article
Language:English
Related URLs:
Identification Number:
edoc DOI:
Last Modified:13 Mar 2018 17:13
Deposited On:21 Jun 2013 12:25

Repository Staff Only: item control page